Risk factor
Very poor trading liquidity
Profitability factor
Very low or no dividends
About
Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producing innovative tools and applications aimed at addressing pressing global health concerns. Geographically, their investment scope includes Europe, the United States, and Israel. Founded in 2011, Flerie AB (publ) is headquartered in Stockholm, Sweden, and also operates a branch office in London, United Kingdom.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.
Target Price
The average target price of FLERIE.ST is 26.0 and suggests 25% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i